UNC Health Care System Selects ARxIUM for Expansion of Shared Services Center
ARxIUM, an industry-leading developer of pharmacy automation, workflow and consulting solutions, today announced the company was selected as vendor of choice by UNC Health Care to further centralize and increase pharmacy operations of its Shared Services Center. The expanded partnership includes the installation of ARxIUM’s pharmacy inventory management software, RxWorks Pro, and high-density inventory storage, FastFind carousels, to better serve pharmacies in the health system’s network.
RxWorks Pro’s integrated, web-based ordering provides UNC Health Care a comprehensive application to manage medication fulfillment of satellite and clinic pharmacy sites. In addition, its business intelligence feature includes customizable dashboards and reporting options that offer better management of medication inventories and real-time response to pharmacy demands. More importantly, the software interoperates with enterprise platforms and other manufacturers’ pharmacy systems and connects with the FastFind carousels to effectively manage medication supplies.
“We are excited by the opportunity to expand our partnership with UNC Health Care and grow its Shared Services Center into one of the most advanced health system pharmacies in the world,” said Dr. Niels Erik Hansen, president and CEO of ARxIUM. “Their innovative, system-wide approach and pharmacy model is the gold standard for other health systems that are looking to centralize and optimize operations. Our multi-phase engagement will result in a highly automated, interoperable Shared Services Center that can effectively onboard and serve pharmacies and clinics throughout the health system.”
ARxIUM’s plan for the UNC Shared Services Center also includes low-density, fixed shelving for higher demand drugs, FastFind carousels for slower moving medications and sortation to manage material flow. FastFind uses a pharmacy’s vertical height to increase the number of items stored in the same footprint by up to 60 percent. The carousel provides barcode scanning, pick-to-light technology and a drug database to enhance patient safety, and has the ability to purchase medications to replenish inventories. The new applications and equipment will complement UNC Health Care’s usage of other ARxIUM systems, including FastPak Elite, an oral solid pouch packaging system, and OptiFill, a high-volume medication fulfillment solution.
“We selected ARxIUM to expand our Shared Services Center because we rely upon their team to provide custom-configured timely solutions,” said Rowell Daniels, system vice president, pharmacy at UNC Health Care System. “Our ongoing partnership has been a collaborative effort that is focused on developing technologies and integrating systems that adapt to our needs. RxWorks, for example, has the ability to handle complex pharmacy situations and improves our cost savings and productivity.”
The UNC Health Care partnership represents the company’s newest approach to servicing its customers. The company consulted with the health system on the future state of its pharmacy operations and helped define the supply delivery system of medications between its hospitals, clinics and Shared Services Center. Additionally, ARxIUM created project specifications and a business case that was technology agnostic, and it recommended pharmacy equipment and automation to achieve patient care and operational objectives. This collaborative, consultative approach is especially important for pharmacies that are considering centralizing or consolidating operations and it serves as a substantial differentiator from competing pharmacy automation providers.
Based in Winnipeg, Manitoba and Buffalo Grove, Illinois, ARxIUM is an industry-leading developer of pharmacy automation, workflow and consulting solutions that improve safety, productivity and workflow. The company provides solutions to shared service centers and health system, hospital, long-term care, retail and government pharmacies. ARxIUM is the developer of the only fully automated IV compounding system in the market today, and offers automated packaging, dispensing, vial filling and high volume systems. In addition, the company provides inventory management, scheduling and workflow software, technical consulting, and system implementation assistance, among other services. ARxIUM is also the creator of the Pharmacy 4.0 approach, which seamlessly converges clinical pharmacy, central production and automation advancements into fully automated, interactive data processes. The approach allows pharmacies to better monitor and react in real-time to address patient care and medication delivery demands. For more information, visit www.arxium.com.
About UNC Health Care
UNC Health Care is an integrated health care system comprised of UNC Hospitals and its provider network, UNC Faculty Physicians, UNC Physicians Network, the clinical patient care programs of the UNC School of Medicine and nine other hospitals and hospital systems across the state. Additional hospital entities include UNC Rex Healthcare, Chatham Hospital, Johnston Health, Pardee Hospital, High Point Regional Health, Caldwell Memorial, Nash Health Care, Wayne Memorial, UNC Lenoir Health Care and UNC Rockingham. For more information, visit www.unchealthcare.org.
Cookerly Public Relations
Cory Stewart, 404-816-2037
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme